iSchemaView today announced that it received registration approval in Japan for its Rapid imaging platform.
The company received registration approval through the Japanese Pharmaceutical Affairs Law and through a third party review by the Japanese Assn. for the Advancement of Medical Equipment for the Rapid imaging platform.
Rapid is designed to give physicians a fast, fully automated and easy-to-interpret imaging system that can help doctors make clinical decisions about stroke.
“Stroke remains the fourth most common cause of death in Japan, and as the population ages, stroke is likely to become an increasing health burden on the country,” National Cerebral & Cardiovascular Center chief of cerebrovascular medicine Dr. Manabu Inoue said in a press release. “With Rapid’s AI-powered imaging technology, we will be able to better address our patients to provide them with the best routes of care, improving their chances of recovery.”
The Rapid technology features artificial intelligence that combines deep learning, machine learning and expert feature extraction, according to iSchemaView. The imaging platform features several fully automated imaging techniques, including Rapid CTP for fully-automated perfusion maps, Rapid MRI for fully-automated diffusion and perfusion maps, Rapid CTA to automatically deliver CT angiography maps and Rapid Aspects to automatically identify early ischemic change on non-contrast CT scans.
Results from the imaging system are delivered through PACS, email, text, the Rapid app or corporate partner workflow systems.
“With approval for Rapid in Japan, we extend a global footprint that gives more hospitals the tools they need to help stroke patients achieve the best outcomes and quality of life,” SVP of worldwide operations Anil Singhal said. “Our goal is to help as many stroke patients as possible by delivering the only clinically validated, next-generation imaging technology available.”